5-[1-fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]-2-naphthyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one

ID: ALA5085615

PubChem CID: 155485030

Max Phase: Preclinical

Molecular Formula: C16H17FN2O6S

Molecular Weight: 384.39

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C[C@H](O)CCOc1ccc2cc(O)c(N3CC(=O)NS3(=O)=O)c(F)c2c1

Standard InChI:  InChI=1S/C16H17FN2O6S/c1-9(20)4-5-25-11-3-2-10-6-13(21)16(15(17)12(10)7-11)19-8-14(22)18-26(19,23)24/h2-3,6-7,9,20-21H,4-5,8H2,1H3,(H,18,22)/t9-/m0/s1

Standard InChI Key:  UUMUNQAHQUYRBJ-VIFPVBQESA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    4.2124  -11.7415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9165  -10.2707    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.7165  -10.4873    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   10.5042   -9.6863    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.0735  -11.7415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0724  -12.5688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7871  -12.9817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7853  -11.3287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5007  -11.7379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5015  -12.5647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2167  -12.9757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9318  -12.5609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9270  -11.7309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2112  -11.3237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6381  -11.3116    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3938  -11.6426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9421  -11.0261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5251  -10.3142    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7631  -11.1074    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.2067  -10.4987    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.6479  -12.9706    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.3589  -11.3292    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6446  -11.7418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9300  -11.3295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5011  -11.3298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2110  -12.5665    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  3  2  2  0
  4  3  2  0
  5  6  2  0
  6  7  1  0
  7 10  2  0
  9  8  2  0
  8  5  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14  9  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18  3  1  0
  3 15  1  0
 13 15  1  0
 17 19  2  0
 14 20  1  0
 12 21  1  0
  5 22  1  0
 22 23  1  0
 23 24  1  0
 24  1  1  0
  1 25  1  0
  1 26  1  1
M  END

Alternative Forms

1. Parent:

   

   ALA5085615

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 384.39

Molecular Weight (Monoisotopic): 384.0791

AlogP: 1.02

#Rotatable Bonds: 5

Polar Surface Area: 116.17

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.77

CX Basic pKa: ┄

CX LogP: 0.26

CX LogD: -0.73

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.71

Np Likeness Score: -0.10

References

1. Abdel-Magid AF..  (2022)  The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.,  13  (1.0): [PMID:35059117] [10.1021/acsmedchemlett.1c00678]

Source

Source(1):

• Scientific Literature